https://scholars.lib.ntu.edu.tw/handle/123456789/487272
標題: | Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma | 作者: | BANG-BIN CHEN CHAO-YU HSU CHIH-WEI YU PO-CHIN LIANG CHIUN HSU CHIH-HUNG HSU ANN-LII CHENG TIFFANY TING-FANG SHIH |
公開日期: | 2017 | 出版社: | Springer Verlag | 卷: | 27 | 期: | 7 | 起(迄)頁: | 3069-3079 | 來源出版物: | European Radiology | 摘要: | Objectives: To correlate early changes in the parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) within 1?week of systemic therapy with overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC). Methods: Eighty-nine patients with advanced HCC underwent DCE-MRI before and within 1?week following systemic therapy. The relative changes of six DCE-MRI parameters (Peak, Slope, AUC, Ktrans, Kep and Ve) of the tumours were correlated with OS using the Kaplan–Meier model and the double-sided log-rank test. Results: All patients died and the median survival was 174?days. Among the six DCE-MRI parameters, reductions in Peak, AUC, and Ktrans, were significantly correlated with one another. In addition, patients with a high Peak reduction following treatment had longer OS (P = 0.023) compared with those with a low Peak reduction. In multivariate analysis, a high Peak reduction was an independent favourable prognostic factor in all patients [hazard ratio (HR), 0.622; P = 0.038] after controlling for age, sex, treatment methods, tumour size and stage, and Eastern Cooperative Oncology Group performance status. Conclusions: Early perfusion changes within 1?week following systemic therapy measured by DCE-MRI may aid in the prediction of the clinical outcome in patients with advanced HCC. Key points: ? DCE-MRI is helpful to evaluate perfusion changes of HCC after systemic treatment. ? Early perfusion changes within 1?week after treatment may predict overall survival. ? High Peak reduction was an independent favourable prognostic factor after systemic treatment. ? 2016, European Society of Radiology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85003977152&doi=10.1007%2fs00330-016-4670-2&partnerID=40&md5=64fc66aaac23fd91c3446c7a7e93bc0a https://scholars.lib.ntu.edu.tw/handle/123456789/487272 |
ISSN: | 0938-7994 | DOI: | 10.1007/s00330-016-4670-2 | SDG/關鍵字: | placebo; sorafenib; UFT; vandetanib; contrast medium; adult; advanced cancer; aged; antiangiogenic activity; area under the curve; Article; cancer chemotherapy; cancer patient; cancer prognosis; cancer survival; clinical outcome; controlled study; dynamic contrast-enhanced magnetic resonance imaging; fatality; female; human; image analysis; Kaplan Meier method; liver cell carcinoma; major clinical study; male; overall survival; perfusion; priority journal; retrospective study; systemic therapy; cancer staging; disease exacerbation; follow up; liver cell carcinoma; liver circulation; liver tumor; magnetic resonance angiography; middle aged; multimodality cancer therapy; physiology; predictive value; prevalence; procedures; survival rate; Taiwan; time factor; trends; vascularization; very elderly; young adult; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Media; Disease Progression; Female; Follow-Up Studies; Humans; Liver Circulation; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prevalence; Survival Rate; Taiwan; Time Factors; Young Adult |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。